Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Immune oncology in hepatocellular carcinoma—hype and hope

The multikinase inhibitor sorafenib was the first systemic agent to show a significant improvement in overall survival for patients with advanced hepatocellular carcinoma, thereby introducing molecularly targeted therapy into this therapeutic field of unmet needs.1 Overall survival benefits are modest, however, and all subsequent agents tested in phase 3 randomised controlled trials (RCTs), both in first-line and second-line settings, have been unable to reach or improve on the magnitude of benefit obtained with sorafenib.